ArticleFrontiers in oncology2026
Development and validation of an interpretable stacking-based risk model for breast cancer- related lymphoedema: a cross-sectional study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast Cancer-Related Lymphedema (BCRL) is one of the common complications after breast cancer treatment. It is characterized by irreversibility and high disability. Currently, early identification of high-risk patients remains a clinical pain point. This study focuses on BCRL risk prediction, integrating machine learning techniques with multi-dimensional clinical data to construct a practical prevention and treatment tool, providing a reference for precise prevention and treatment of BCRL. Methods: Patients who underwent breast cancer surgery and treatment from January 2021 to May 2025 were included. The diagnostic criterion for BCRL was "the difference in upper limb circumference ≥2 cm". Using LASSO regression, Support Vector Machine Recursive Feature Elimination (SVM-REF), Random Forest (RF) and Boruta, 34 variables were subjected to feature selection, and features selected by all four algorithms were used as modeling variables. The SHAP value analysis was performed to construct and validate an interpretable BCRL risk prediction model using a Stacking ensemble learning approach, and a visual Web-based risk prediction tool was developed. Results: A total of 570 eligible patients were included. They were stratified into the training set (420 cases) and the temporal validation set (150 cases). Seven core characteristics were selected, including clinical characteristics (BMI, tumor clinical stage, surgical method, axillary lymph node handling method and diabetes) and modifiable characteristics (patients' awareness of BCRL and the time spent holding their mobile phones daily after surgery). The Stacking model performed the best, featuring high accuracy, high precision and interpretability. The ROC-AUC values for the training and validation sets were 0.911 and 0.868, respectively, and the PR-AUC values were 0.857 and 0.789, respectively. The Web tool, StackBCRL, can be accessed online. Conclusions: Through the construction of an interpretable BCRL risk prediction model based on Stacking ensemble learning by integrating postoperative behavioral characteristics (the time spent holding their mobile phones daily after surgery and patients' awareness of BCRL), the developed BCRL risk assessment system achieved real-time individualized risk prediction and visualization. It provides a simple and practical method for large-scale, low-cost early screening of BCRL, is suitable for promoting clinical application and provides an innovative solution for BCRL prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.